PC3I Announces Leadership Transition
October 7, 2024
Founding Director Justin Bekelman Leaving; Deputy Director Katharine Rendle Appointed as Successor.
Six years after founding PC3I, Director Justin Bekelman, MD is stepping down to pursue a new endeavor in cancer care transformation in the private sector. This week, the Abramson Cancer Center announced the appointment of Katharine Rendle, PhD, MSW, MPH as PC3I’s next Director. Dr. Bekelman will remain on as a member of PC3I’s faculty.
As PC3I’s current Deputy Director, Dr. Rendle currently heads several large-scale projects, including Penn TRACE, one of four National Cancer Institute centers focused on advancing telehealth research to improve cancer care and health outcomes. In addition, she co-leads Penn’s Lung PROSPR Research Center, which examines utilization and outcomes of lung cancer screening across diverse populations in five different community-based healthcare systems across the U.S. On the national level, Dr. Rendle is an appointed member of the NCI’s Board of Scientific Advisors.
In her new role, effective October 1, 2024, Dr. Rendle will further PC3I’s innovative approach of working at the nexus of research and practice to create, test, and scale solutions to transform cancer care delivery. We thank Dr. Bekelman for his visionary leadership in founding PC3I and invite you to join us in celebrating Dr. Rendle’s appointment as PC3I’s next Director.
